Project information
Excellence in research and development of non-coding RNA DIAGnostics in ONcology
(RNADIAGON)
- Project Identification
- 824036
- Project Period
- 2/2019 - 7/2024
- Investor / Pogramme / Project type
-
European Union
- Horizon 2020
- MSCA Marie Skłodowska-Curie Actions (Excellent Science)
- MU Faculty or unit
- Central European Institute of Technology
- Cooperating Organization
-
Universita degli studi di Ferrara
BioVendor - Laboratorní medicína, a.s.
Medical University of Graz
University Hospital Hamburg-Eppendorf
University of Medicine and Pharmacy Iuliu Haţieganu Cluj-Napoca
The University of Texas MD Anderson Cancer Center
Project RNADIAGON aims at development of personal skills and knowledge of early-stage and experienced researchers working in the field of non-coding RNA diagnostics in oncology from 5 European (EU) academic centers (Masaryk University, CEITEC, Czech Republic; University Medical Center Hamburg-Eppendorf, Germany; Iuliu Hatieganu University of Medicine and Pharmacy, Romania; University of Ferrara, Italy; Medical University of Graz, Austria) through their (i) long-term stays at the US research center of excellence (MD Anderson Cancer Center, University of Texas, USA) and (ii) traineeships at the education center and manufacturing facilities of industrial partner (BioVendor, Inc.) developing certified (CE IVD) diagnostics, who will work on the development of a new non-coding RNA diagnostic kit in colorectal cancer adopted here as a model project. This research and innovation staff exchange will increase the scientific excellence and quality of related research in the participating EU research institutions, and enable the dissemination of new technologies and approaches related to this field among other EU research institution as well as interested public.
Sustainable Development Goals
Masaryk University is committed to the UN Sustainable Development Goals, which aim to improve the conditions and quality of life on our planet by 2030.
Publications
Total number of publications: 11
2024
-
Non-Coding RNAs in Peritoneal Carcinomatosis: From Bench to Bedside
Cancers, year: 2024, volume: 16, edition: 17, DOI
2023
-
Combination of Urinary MiR-501 and MiR-335 With Current Clinical Diagnostic Parameters as Potential Predictive Factors of Prostate Biopsy Outcome
CANCER GENOMICS & PROTEOMICS, year: 2023, volume: 20, edition: 3, DOI
2021
-
circFOXO3: Going around the mechanistic networks in cancer by interfering with miRNAs regulatory networks
Biochimica et Biophysica Acta - Molecular Basis of Disease, year: 2021, volume: 1867, edition: 5, DOI
2020
-
Circulating Non-coding RNAs in Renal Cell Carcinoma-Pathogenesis and Potential Implications as Clinical Biomarkers
Frontiers in Cell and Developmental Biology, year: 2020, volume: 8, edition: SEP, DOI
-
lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System
Cancers, year: 2020, volume: 12, edition: 8, DOI
-
Long Non-Coding RNA PANTR1 is Associated with Poor Prognosis and Influences Angiogenesis and Apoptosis in Clear-Cell Renal Cell Cancer
Cancers, year: 2020, volume: 12, edition: 5, DOI
-
Tiny Actors in the Big Cellular World: Extracellular Vesicles Playing Critical Roles in Cancer
International Journal of Molecular Sciences, year: 2020, volume: 21, edition: 20, DOI
2019
-
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Cancers, year: 2019, volume: 11, edition: 10, DOI
-
Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma
Cancers, year: 2019, volume: 11, edition: 10, DOI
-
Evaluation of miRNA detection methods for the analytical characteristics necessary for clinical utilization
Biotechniques, year: 2019, volume: 66, edition: 6, DOI